174 related articles for article (PubMed ID: 22470924)
1. [A new clinical disease entity. Tuberculosis in users of TNF-alpha inhibitors].
Trautmann M
Pharm Unserer Zeit; 2012 Jan; 41(1):79-83. PubMed ID: 22470924
[No Abstract] [Full Text] [Related]
2. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
3. The yin and yang of tumor necrosis factor inhibitors.
Calabrese L
Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
[TBL] [Abstract][Full Text] [Related]
4. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
5. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
6. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
7. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
8. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
9. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab.
Puxeddu I; Giori L; Rocchi V; Bazzichi L; Bombardieri S; Tavoni A; Migliorini P; Del Corso I
Ann Allergy Asthma Immunol; 2012 Feb; 108(2):123-4. PubMed ID: 22289732
[No Abstract] [Full Text] [Related]
11. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period.
Conti F; Scrivo R; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
Clin Exp Rheumatol; 2009; 27(3):540-1. PubMed ID: 19604456
[No Abstract] [Full Text] [Related]
12. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
Titos Arcos JC; Hallal H; Robles M; Andrade RJ
Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
[No Abstract] [Full Text] [Related]
13. [Safety of anti-TNFα biological drugs].
Trotta F; Valentini G
Reumatismo; 2005; 57(4 Suppl):34-9. PubMed ID: 16385354
[TBL] [Abstract][Full Text] [Related]
14. [TNF targetting therapy for rheumatoid arthritis].
Takeuchi T
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
[No Abstract] [Full Text] [Related]
15. Which TNF inhibitor for rheumatoid arthritis?
Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
[No Abstract] [Full Text] [Related]
16. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
Neovius M; Askling J
Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
[No Abstract] [Full Text] [Related]
17. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].
Xie X; Chen J; Peng Y; Gao J; Tian J; Ling G; Du J; Mao N; Wu P; Li F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
19. [Approved indications and other possible utilizations of anti-TNFα biologic drugs].
Grassi W; Montecucco C
Reumatismo; 2005; 57(4 Suppl):30-3. PubMed ID: 16385353
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]